
KMTS Stock Forecast & Price Target
KMTS Analyst Ratings
Bulls say
Kestra Medical Techs is a commercial-stage MedTech company that has developed the ASSURE Cardiac Recovery System, which includes the ASSURE wearable cardioverter defibrillator (WCD). The company has shown strong growth in its prescription volume, driven by market share gains and new account activations, and has a well-positioned salesforce and partnerships for further expansion. We expect continued revenue growth and gross margin expansion, warranting a Buy rating and $32 price target based on 10x our 12-24 month revenue forecast, in light of KMTS's early stage of commercial ramp, high growth rate, and potential for further improvements in profitability, as well as a duopoly market and lengthy growth runway. Risks to our outlook include potential challenges in commercial execution, regulatory decision, and competition.
Bears say
Kestra Medical Techs is currently in the early stages of its commercial ramp and is experiencing high sales growth. However, there are risks to their commercial execution, as well as concerns about regulatory and reimbursement decisions, competition, and their balance sheet. Our Buy rating is based on a $32 price target, which is 10x our revenue forecast for the next 12-24 months.
This aggregate rating is based on analysts' research of Kestra Medical Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
KMTS Analyst Forecast & Price Prediction
Start investing in KMTS
Order type
Buy in
Order amount
Est. shares
0 shares